Details
Event Materials
The 2025 ISPE Annual Meeting took place in Washington, D.C., from August 22–26, showcasing a wide array of Sentinel-related work through presentations, posters, and more. You can now explore the materials from each session and poster below.
Spotlight Poster
Symposia
- Addressing the Threat of Confounding in Pharmacoepidemiology with Innovative Methods: Lessons from the FDA Sentinel Innovation Center
- Developing Computable Phenotypes for Medical Product Safety Surveillance: Innovative Methods and Data Sources
- Insights on Harmonizing Laboratory Results Data in the Sentinel System
- Drug Shortage Surveillance: Exploration of Real-World Data
- The Future of Pharmacovigilance: Accelerating Signal Identification with Electronic Healthcare Data
Oral Presentation
Posters
- Assessment of Utilization Patterns of New Molecular Entities Approved in 2022 using the Sentinel Distributed Database
- Attention-Deficit/Hyperactivity Disorder Medication Utilization Among U.S. Adults Ages 18-64 Years with Commercial Insurance or Medicare: Implications for Design of Inferential Safety Studies
- Cannabis-Related Healthcare Encounters Among Commercially Insured Adults Aged 18-64 years Contributing Data to the US Food and Drug Administration’s Sentinel, 2017-2022
- Characterization of Confounding Covariate Data Capture in the U.S. Food and Drug Administration’s Sentinel Distributed Database
- Electronic Health Record (EHR) Enhanced Signal Detection Using Tree-Based Scan Statistic Methods
- Prevalence of Key Confounding Covariates in a Commercial Electronic Health Records Platform
- Risk of Diabetic Ketoacidosis Across Stages of Chronic Kidney Disease in Patients with Type 1 Diabetes in the U.S. Food and Drug Administration’s Sentinel System
- Risk of Incident Inflammatory Bowel Disease in New Users of Dipeptidyl Peptidase 4 Inhibitors, Sodium Glucose Cotransporter 2 Inhibitors, or Sulfonylurea in the U.S. Food and Drug Administration’s Sentinel System
- Self-Reported Use of Non-FDA Approved Cannabinoid Products Among Hospitalized Patients in a Large U.S. Hospital Network
- Single-Dose Doxycycline for Lyme Disease Prophylaxis in Children in a Large United States Healthcare Database, 2016-2020
- Strengthening Inferential Studies in the U.S. FDA Sentinel Initiative: Results from a Methodological Demonstration Project
- Use of Glucagon-Like Peptide-1 Receptor Agonists in the U.S. Food and Drug Administration’s Sentinel System
- Utilization of Hormonal Contraceptives During the Postpartum Period in the FDA Sentinel System
- Utilization of Type 2 Diabetes Mellitus Products in the Sentinel Distributed Database, 2008-2024
More information on the conference can be found here.